Amylyx Pharmaceuticals Inc (AMLX)
1.71
-0.03
(-1.72%)
USD |
NASDAQ |
Jun 12, 16:00
1.72
+0.01
(+0.58%)
After-Hours: 07:45
Amylyx Pharmaceuticals Shareholders Equity (Quarterly): 324.44M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 324.44M |
December 31, 2023 | 433.43M |
September 30, 2023 | 418.40M |
June 30, 2023 | 386.36M |
March 31, 2023 | 352.65M |
December 31, 2022 | 340.61M |
Date | Value |
---|---|
September 30, 2022 | 144.03M |
June 30, 2022 | 192.79M |
March 31, 2022 | 240.95M |
December 31, 2021 | -151.17M |
September 30, 2021 | -124.07M |
December 31, 2020 | -66.72M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-151.17M
Minimum
Dec 2021
433.43M
Maximum
Dec 2023
207.64M
Average
282.69M
Median
Shareholders Equity (Quarterly) Benchmarks
iRhythm Technologies Inc | 90.29M |
Cassava Sciences Inc | 78.60M |
Bristol-Myers Squibb Co | 16.49B |
Moderna Inc | 12.82B |
ACADIA Pharmaceuticals Inc | 464.04M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 417.46M |
Total Liabilities (Quarterly) | 93.02M |
Current Ratio | 4.480 |